These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 30841886)

  • 1. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
    Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
    BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.
    Richter A; Sender S; Lenz A; Schwarz R; Hinz B; Knuebel G; Sekora A; Murua Escobar H; Junghanss C; Roolf C
    BMC Cancer; 2020 Mar; 20(1):184. PubMed ID: 32131762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.
    Buontempo F; Orsini E; Martins LR; Antunes I; Lonetti A; Chiarini F; Tabellini G; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Cappellini A; Barata JT; Martelli AM
    Leukemia; 2014 Mar; 28(3):543-53. PubMed ID: 24253024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels.
    Gomes AM; Soares MV; Ribeiro P; Caldas J; Póvoa V; Martins LR; Melão A; Serra-Caetano A; de Sousa AB; Lacerda JF; Barata JT
    Haematologica; 2014 Jun; 99(6):1062-8. PubMed ID: 24561792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
    Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
    Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous Inhibition of Protein Kinase CK2 and Dihydrofolate Reductase Results in Synergistic Effect on Acute Lymphoblastic Leukemia Cells.
    Wińska P; Widło Ł; Skierka K; Krzyśko A; Koronkiewicz M; Cieśla JM; Cieśla J; Bretner M
    Anticancer Res; 2019 Jul; 39(7):3531-3542. PubMed ID: 31262877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia.
    Ge Z; Song C; Ding Y; Tan BH; Desai D; Sharma A; Gowda R; Yue F; Huang S; Spiegelman V; Payne JL; Reeves ME; Iyer S; Dhanyamraju PK; Imamura Y; Bogush D; Bamme Y; Yang Y; Soliman M; Kane S; Dovat E; Schramm J; Hu T; McGrath M; Chroneos ZC; Payne KJ; Gowda C; Dovat S
    Leukemia; 2021 May; 35(5):1267-1278. PubMed ID: 33531656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional Regulation of PIK3CD and PIKFYVE in T-Cell Acute Lymphoblastic Leukemia by IKAROS and Protein Kinase CK2.
    Dovat E; Song C; Hu T; Rahman MA; Dhanyamraju PK; Klink M; Bogush D; Soliman M; Kane S; McGrath M; Ding Y; Desai D; Sharma A; Gowda C
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia.
    Kuang SQ; Fang Z; Zweidler-McKay PA; Yang H; Wei Y; Gonzalez-Cervantes EA; Boumber Y; Garcia-Manero G
    PLoS One; 2013; 8(4):e61807. PubMed ID: 23637910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.
    Bliesath J; Huser N; Omori M; Bunag D; Proffitt C; Streiner N; Ho C; Siddiqui-Jain A; O'Brien SE; Lim JK; Ryckman DM; Anderes K; Rice WG; Drygin D
    Cancer Lett; 2012 Sep; 322(1):113-8. PubMed ID: 22387988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.
    Bian Y; Han J; Kannabiran V; Mohan S; Cheng H; Friedman J; Zhang L; VanWaes C; Chen Z
    Int J Biol Sci; 2015; 11(4):411-22. PubMed ID: 25798061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
    Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
    Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of cellular proliferation in acute lymphoblastic leukemia by Casein Kinase II (CK2) and Ikaros.
    Gowda C; Song C; Kapadia M; Payne JL; Hu T; Ding Y; Dovat S
    Adv Biol Regul; 2017 Jan; 63():71-80. PubMed ID: 27666503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
    Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis.
    Negi SS; Brown P
    Oncotarget; 2015 Jul; 6(20):18094-104. PubMed ID: 26061708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.
    Zheng Y; McFarland BC; Drygin D; Yu H; Bellis SL; Kim H; Bredel M; Benveniste EN
    Clin Cancer Res; 2013 Dec; 19(23):6484-94. PubMed ID: 24036851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The synergistic therapeutic effect of imatinib and protein kinase CK2 Inhibition correlates with PI3K-AKT activation in gastrointestinal stromal tumors.
    Zhou L; Wang H; Liu H; Huang Z; Wang Z; Zhou X; Mu X
    Clin Res Hepatol Gastroenterol; 2022; 46(6):101886. PubMed ID: 35183792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.
    Quotti Tubi L; Gurrieri C; Brancalion A; Bonaldi L; Bertorelle R; Manni S; Pavan L; Lessi F; Zambello R; Trentin L; Adami F; Ruzzene M; Pinna LA; Semenzato G; Piazza F
    J Hematol Oncol; 2013 Oct; 6():78. PubMed ID: 24283803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia.
    Song C; Ge Z; Ding Y; Tan BH; Desai D; Gowda K; Amin S; Gowda R; Robertson GP; Yue F; Huang S; Spiegelman V; Payne JL; Reeves ME; Gurel Z; Iyer S; Dhanyamraju PK; Xiang M; Kawasawa YI; Cury NM; Yunes JA; McGrath M; Schramm J; Su R; Yang Y; Zhao Z; Lyu X; Muschen M; Payne KJ; Gowda C; Dovat S
    Blood; 2020 Sep; 136(13):1520-1534. PubMed ID: 32396934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.